Abacavir coadministration does not interfere with the suppressive activity of ribavirin in an HCV replicon system.

摘要: BACKGROUND: HCV is a major cause of morbidity and mortality in HIV-coinfected patients. Several observational studies have suggested that response to pegylated interferon ribavirin lower patients treated with abacavir. It has been postulated abacavir could compete be phosphorylated, leading reduction the active form drug (triphosphorylated ribavirin). Here, we studied effect abacavir, tenofovir or lamivudine addition on suppressive activity an RNA replicon system. METHODS: We used human hepatoma HuH-7 cell clone 9B containing genotype 1b I389/NS3-3'. Cells were for 24 h (0, 10 50 μM) plus at doses 0, μM production was quantified by real-time PCR triplicate assays. Results expressed as mean±SD produced per (log(10) IU/cell). Means compared using Student's t-test. RESULTS: Ribavirin treatment dose-dependent suppression Combination resulted additive antiviral activity. The did not modify expression. Similar results obtained when combination lamivudine. CONCLUSIONS: In subgenomic system, modified